TY - JOUR
T1 - Update upon efficacy and safety of TNF-α inhibitors
AU - Murdaca, Giuseppe
AU - Colombo, Barbara Maria
AU - Cagnati, Paola
AU - Gulli, Rossella
AU - Span, Francesca
AU - Puppo, Francesco
PY - 2012/1
Y1 - 2012/1
N2 - The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, that is, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. This editorial discusses the recent indications of TNF-α inhibitors, the pretreatment considerations, the reported adverse events and, finally, the recommendations for its use in pregnancy.
AB - The ongoing progresses in the knowledge of the pathogenic mechanisms of various immune-mediated and inflammatory diseases as well as the availability of innovative biotechnological approaches have led to the development of new drugs that add to conventional treatments. Among these, tumor necrosis factor (TNF)-α inhibitors, that is, infliximab, adalimumab, etanercept, golimumab and certolizumab pegol, are now available for clinical use. This editorial discusses the recent indications of TNF-α inhibitors, the pretreatment considerations, the reported adverse events and, finally, the recommendations for its use in pregnancy.
KW - Efficacy
KW - Immune-mediated diseases
KW - Safety
KW - TNF-α inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84555190230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84555190230&partnerID=8YFLogxK
U2 - 10.1517/14740338.2012.630388
DO - 10.1517/14740338.2012.630388
M3 - Article
C2 - 22010813
AN - SCOPUS:84555190230
VL - 11
SP - 1
EP - 5
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 1
ER -